Skip to main content
SpringerLink
Log in

Pseudoprogression in Gliomas: the Use of Advanced MRI for Treatment Decisions

  • Neuro-oncology (R Soffietti, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Abstract

Purpose of review

The definitions of pseudoprogression (PsP) have greatly varied with time, with a reported incidence ranging from 10 to 30%. PsP is mainly a radiological definition, as a new or enlarging area of contrast agent enhancement, without argument of true tumor progression (TP), which will resolve or stabilize without any change in treatment. Because anatomical magnetic resonance imaging (MRI) is unsatisfactory in differentiating PsP from TP, advanced MR techniques are needed, adding sensitivity and specificity to obtain a more solid diagnosis.

Recent findings

Because of its high reported diagnostic accuracy, perfusion MR seems to be the most reliable technique to better identify PsP, the lack of standardization of MR spectroscopy compromising its availability in daily practice.

Summary

A multi-modal and dynamic MR approach is recommended, after harmonization of image acquisition and post-processing. Due to the recent interest of immunotherapies, identifying PsP will continue to be an issue, particularly in better including true progressing patients in clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–72.

    Article  PubMed  Google Scholar 

  2. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9(5):453–61.

    Article  PubMed  Google Scholar 

  3. Rowe LS, Butman JA, Mackey M, Shih JH, Cooley-Zgela T, Ning H, et al. Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM. J Neurooncol. 2018;139(1):145–52.

    Article  PubMed  Google Scholar 

  4. • van Dijken BRJ, van Laar PJ, Holtman GA, van der Hoorn A. Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis. Eur Radiol. 2017;27(10):4129–44. Exhaustive meta-analysis on the subject of pseudoprogression.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Yoo R-E, Choi SH, Kim TM, Lee S-H, Park C-K, Park S-H, et al. Independent poor prognostic factors for true progression after radiation therapy and concomitant temozolomide in patients with glioblastoma: subependymal enhancement and low ADC value. AJNR Am J Neuroradiol. 2015;36(10):1846–52.

    Article  PubMed  Google Scholar 

  6. Young RJ, Gupta A, Shah AD, Graber JJ, Zhang Z, Shi W, et al. Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology. 2011;76(22):1918–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Mullins ME, Barest GD, Schaefer PW, Hochberg FH, Gonzalez RG, Lev MH. Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. AJNR Am J Neuroradiol. 2005;26(8):1967–72.

    PubMed  Google Scholar 

  8. Dalesandro MF, Andre JB. Posttreatment evaluation of brain gliomas. Neuroimaging Clin N Am. 2016;26(4):581–99.

    Article  PubMed  Google Scholar 

  9. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology. 1986;161(2):401–7.

    Article  PubMed  Google Scholar 

  10. Garcia GCTE, Bockel S, Majer M, Ammari S, Smits M. Imaging of brain metastases: diagnosis and monitoring. In: Ahluwalia M, Metellus P, Soffietti R, editors. Central nervous system metastases. Cham: Springer; 2020.

    Google Scholar 

  11. Prager AJ, Martinez N, Beal K, Omuro A, Zhang Z, Young RJ. Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. AJNR Am J Neuroradiol. 2015;36(5):877–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kazda T, Bulik M, Pospisil P, Lakomy R, Smrcka M, Slampa P, et al. Advanced MRI increases the diagnostic accuracy of recurrent glioblastoma: single institution thresholds and validation of MR spectroscopy and diffusion weighted MR imaging. NeuroImage Clin. 2016;11:316–21.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Chu HH, Choi SH, Ryoo I, Kim SC, Yeom JA, Shin H, et al. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. Radiology. 2013;269(3):831–40.

    Article  PubMed  Google Scholar 

  14. Song YS, Choi SH, Park C-K, Yi KS, Lee WJ, Yun TJ, et al. True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis. Korean J Radiol. 2013;14(4):662–72.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Liu Z-C, Yan L-F, Hu Y-C, Sun Y-Z, Tian Q, Nan H-Y, et al. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial. BMC Med Imaging. 2017;17(1):10.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Wang S, Martinez-Lage M, Sakai Y, Chawla S, Kim SG, Alonso-Basanta M, et al. Differentiating tumor progression from pseudoprogression in patients with glioblastomas using diffusion tensor imaging and dynamic susceptibility contrast MRI. AJNR Am J Neuroradiol. 2016;37(1):28–36.

    Article  PubMed  Google Scholar 

  17. Agarwal A, Kumar S, Narang J, Schultz L, Mikkelsen T, Wang S, et al. Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression. J Neurooncol. 2013;112(3):413–20.

    Article  PubMed  Google Scholar 

  18. Patel P, Baradaran H, Delgado D, Askin G, Christos P, John Tsiouris A, et al. MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis. Neuro-Oncol. 2017;19(1):118–27.

    Article  PubMed  Google Scholar 

  19. Choi YJ, Kim HS, Jahng G-H, Kim SJ, Suh DC. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging. Acta Radiol. 2013;54(4):448–54.

    Article  PubMed  Google Scholar 

  20. Nyberg E, Honce J, Kleinschmidt-DeMasters BK, Shukri B, Kreidler S, Nagae L. Arterial spin labeling: pathologically proven superiority over conventional MRI for detection of high-grade glioma progression after treatment. Neuroradiol J. 2016;29(5):377–83.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Bulik M, Kazda T, Slampa P, Jancalek R. The diagnostic ability of follow-up imaging biomarkers after treatment of glioblastoma in the temozolomide era: implications from proton MR spectroscopy and apparent diffusion coefficient mapping. Biomed Res Int. 2015;2015:641023.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Guivel-Scharen V, Sinnwell T, Wolff SD, Balaban RS. Detection of proton chemical exchange between metabolites and water in biological tissues. J Magn Reson. 1998;133(1):36–45.

    Article  CAS  PubMed  Google Scholar 

  23. Ma B, Blakeley JO, Hong X, Zhang H, Jiang S, Blair L, et al. Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas. J Magn Reson Imaging. 2016;44(2):456–62.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Mehrabian H, Desmond KL, Chavez S, Bailey C, Rola R, Sahgal A, et al. Water exchange rate constant as a biomarker of treatment efficacy in patients with brain metastases undergoing stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2017;98(1):47–55.

    Article  PubMed  Google Scholar 

  25. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, They Are Data. Radiology. 2016;278(2):563–77.

    Article  PubMed  Google Scholar 

  26. Chen X, Wei X, Zhang Z, Yang R, Zhu Y, Jiang X. Differentiation of true-progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide by GLCM texture analysis of conventional MRI. Clin Imaging. 2015;39(5):775–80.

    Article  PubMed  Google Scholar 

  27. • Wick W, Chinot OL, Bendszus M, Mason W, Henriksson R, Saran F, et al. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro-Oncol. 2016;18(10):1434–41. This study in one of the only studying pseudoprogression and the timing to assess it with prospectively collected data.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Di Giacomo AM, Danielli R, Guidoboni M, Calabrò L, Carlucci D, Miracco C, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 2009;58(8):1297–306.

    Article  PubMed  Google Scholar 

  29. Roth P, Valavanis A, Weller M. Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab. Neuro-Oncol. 2017;19(3):454–6.

    PubMed  Google Scholar 

  30. • Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16(15):e534–42. This study introduces a promising new way of assessing tumor response in patients treated for gliomas with immunotherapy.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Gustave Roussy University Hospital, 114 rue Edouard Vaillant, 94805, Villejuif Cedex, France

    Gabriel C. T. E. Garcia MD, MSc

  2. Department of Radiation Oncology, Gustave Roussy University Hospital, 114 rue Edouard Vaillant, 94805, Villejuif Cedex, France

    Frédéric Dhermain MD, PhD

Authors
  1. Gabriel C. T. E. Garcia MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frédéric Dhermain MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gabriel C. T. E. Garcia MD, MSc.

Ethics declarations

Conflict of Interest

Gabriel C.T.E. Garcia declares that he has no conflict of interest.

Frédéric Dhermain declares that he has no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Neuro-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garcia, G.C.T.E., Dhermain, F. Pseudoprogression in Gliomas: the Use of Advanced MRI for Treatment Decisions. Curr Treat Options Neurol 22, 23 (2020). https://doi.org/10.1007/s11940-020-00630-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-020-00630-8

Keywords

Search

Navigation